Madrigal Pharmaceuticals (MDGL) PT Raised to $536 at BofA Securities
April 30, 2026 9:10 AM
BofA Securities analyst Jason Zemansky raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $536.00 (from $529.00) while maintaining a Neutral rating.
